Stocks Down Under Videos
Get a 3-month FREE TRIAL to CONCIERGE now!
Concierge gives you timely BUY and SELL alerts on ASX-listed stocks
Dimerix’s Phase 3 interim results were encouraging! Interview with CEO Dr. Nina Webster
March 21, 2024
Dimerix, DXB
Dimerix (ASX:DXB)
We spoke with Dr. Nina Webster, CEO of Dimerix (ASX: DXB), about the company’s encouraging interim results in the Phase 3 study of DMX-200 in Focal Segmental Glomerulosclerosis.
This first interim analysis of the ACTION3 trial showed that the drug had performed well based on the proteinuria efficacy endpoint of the study. This suggests that DMX-200 may result in improvement in kidney function when included in the standard of care in patients with FSGS.
Check out this recent interview with Dimerix as well!
What are the Best ASX Life Sciences Stocks to invest in right now?
Check our ASX buy/sell tips
